Nov. 6 at 9:14 PM
$TXG Revenue was
$149.0 million for the third quarter, compared to
$172.9 million in the second quarter, which included
$27.3 million related to one-time license and royalty revenue. Third quarter revenue represents a 2% increase sequentially, excluding the second quarter one-time license and royalty revenue. • Started shipping the next-generation of Chromium Flex, delivering cost-effective, highly-scalable, plate-based single cell analysis and empowering researchers to explore a broad range of studies. • Launched Xenium Protein, the first fully-integrated spatial multiomic workflow enabling simultaneous RNA and protein detection on the same tissue section in a single automated run. • Ended the third quarter with cash and cash equivalents and marketable securities of
$482.1 million, representing a
$35 million increase over the prior quarter.
